Key takeaways
- There is no adequate randomized human evidence that BPC-157 does what it's sold to do.
- Almost all the research is cell and animal injury models. The human mechanism is unestablished.
- 22 vendors list it, tied for most in our market. Only 5 published lab records exist in our ledger.
- It's the clearest case of popularity and evidence moving in opposite directions.
What BPC-157 is
If you've spent any time in fitness or recovery communities, you've met this one. It's the peptide people bring up for a stubborn tendon, a bad gut, an injury that won't close out.
It's a chain of 15 amino acids, which is why you'll see it called a pentadecapeptide. The full name is Body Protection Compound-157.
It's described as derived from a protein found in gastric juice, and that origin story does a lot of persuasive work. A molecule your stomach already makes, involved in protecting tissue, sounds like something that ought to help tissue heal.
Sounding plausible is where the evidence stops.
Our profile is blunt about the mechanism: the human mechanism is unestablished, and the proposed nitric-oxide, angiogenesis, vascular, and tissue-repair pathways come largely from preclinical work.
Those pathways are real biology. What's missing is evidence that any of it produces a result in a person.
What the evidence actually consists of
Here's the plain version, and it's shorter than you'd expect from the volume of discussion.
There is no adequate randomized human evidence establishing recovery, musculoskeletal, or gastrointestinal benefit.
The research is dominated by cell and animal injury models. Rats with induced wounds, tissue in dishes, controlled damage in laboratory settings.
We rate it very low evidence with an early signal, and it sits in the bottom tier of our research directory alongside GHK-Cu, MOTS-c, and TB-500.1
Animal injury work is genuine science. It's how you decide a hypothesis deserves a trial, and it is not a substitute for one.
| What exists | What doesn't |
|---|---|
| Cell and animal injury models | Adequate randomized human trials |
| Proposed repair pathways | An established human mechanism |
| Extensive community discussion | A regulator-approved use |
A mechanism that explains why something might work is not evidence that it does. BPC-157 is the compound where that distinction gets collapsed most often, in both directions: sellers imply the animal work is clinical, and critics sometimes imply there's no science at all. Neither is right.
Worth knowing that the collapse isn't just sloppy. Presenting preclinical work as though it established a health benefit is the kind of claim advertising regulators treat as unsupported.2
The popularity gap
This is where our own data says something useful.
BPC-157 is listed by 22 vendors in our price market, tied with GHK-Cu and MOTS-c for the most of any compound we track. It's the most-searched peptide that has nothing to do with weight loss.
And it has the weakest evidence tier we assign.
| Compound | Vendors | Our evidence rating | Status |
|---|---|---|---|
| BPC-157 | 22 | Very low | Not approved |
| GHK-Cu | 22 | Very low | Not approved |
| MOTS-c | 22 | Very low | Not approved |
| Semaglutide | 2 | High | FDA approved |
Vendor counts from our price market, checked 25 July 2026.
Across the compounds we track, the number of sellers runs opposite to the strength of the evidence. The three with the most vendors all sit at the bottom of our ratings, and the one with the strongest evidence has the fewest sellers.
There's no conspiracy in that. Approved drugs live inside prescriptions, pharmacies, and liability, and unapproved compounds don't, so they're simply easier to stock and easier to talk about.
But it does mean you cannot read anything about a compound's evidence from how available it is. We unpack that pattern properly in why evidence maturity beats online momentum.
The testing gap is worse
22 vendors sell it. Our testing ledger holds five published lab records for it.3
Compare that to 44 for retatrutide and 33 for tirzepatide, both sold by three vendors or fewer.
So the compound with the most sellers has almost the least published lab evidence. Five records cannot characterise what 22 storefronts are shipping.
What the five do show is consistent with the rest of our ledger:
| Result across 5 records | |
|---|---|
| Identity confirmed | Every record |
| Purity range | 99.50% to 99.79% |
| Vials measuring over label | 5 of 5 |
| Median variance | +11.1% |
| Range | +6.2% to +13.4% |
Clean material, every vial over its labelled dose, by around 11% at the midpoint.
Five samples is too few to generalise from, and that is the point. For the most widely sold repair peptide on the market, there is almost nothing published to check.
What it costs
BPC-157 runs $29.95 to $149.99 across those 22 vendors, as of our 25 July 2026 check.
A 5x spread on the same named compound, and those are package prices covering different vial sizes rather than quality tiers.
With 22 sellers and no approved product to anchor against, there's nothing holding the price to anything. Our vendor checklist covers what to actually look for instead.
Where BPC-157 sits
The honest summary is uncomfortable for everyone.
The biology isn't nonsense. There's real preclinical work behind it, and it's the reason the compound gets taken seriously.
The human evidence isn't there. No adequate randomized trials, no established human mechanism, no approval.
The supply is barely documented. Five published lab records against 22 sellers.
So the useful question isn't whether BPC-157 works. It's whether you're comfortable making a decision on animal data and five certificates, which is a question about your own risk tolerance rather than about the science.
Nothing in the evidence supports treating this as established. That's a statement about the state of the research, and it's the most definitive thing anyone can honestly say right now.
Profile with graded outcomes and sources: BPC-157. Related reading: what peptides actually are and how to evaluate a vendor.
Frequently asked questions
Is BPC-157 FDA approved?
No. It is not approved by the FDA for any use, and it is sold labelled for research rather than for human use. It has also been flagged in the context of substances excluded from pharmacy compounding, which is a separate regulatory question from approval.
Are there human studies on BPC-157?
Not adequate ones. Our profile states plainly that there is no adequate randomized human evidence establishing recovery, musculoskeletal, or gastrointestinal benefit. The body of research is dominated by cell and animal injury models, which can justify further study but cannot establish a clinical outcome.
Why is BPC-157 so popular if the evidence is weak?
Because the story is appealing and easy to repeat, and because nothing about the market restrains it. Compounds that were never approved sit outside the prescription system, which makes them easier to sell and easier to discuss. Popularity measures how easy something is to sell, not whether it works.
How is BPC-157 sold if it isn't approved?
As material labelled for research use only. That label is doing legal work rather than quality work: it does not mean the product has been assessed for human use, and it does not confer any of the oversight an approved product carries.
Read next
Educational information only. This article does not recommend a treatment, supplier, dose, or medical decision. See how we evaluate evidence.